Patricio Massera was appointed Chief Executive Officer of AGC Biologics (formerly CMC Biologics) in May 2019. Patricio joined the company in 2012, as General Manager of Copenhagen-based CMC Biologics A/S. He later served as Chief Operating Officer in the Seattle-based company headquarters. As CEO, Patricio quickly developed a comprehensive people management strategy, recognizing that with a healthy company culture and highly engaged employees, AGC is best positioned to provide the highest-quality services to our customers. Across his 20 years of biologics experience, Patricio held several key executive positions at MSD AH, Intervet/Schering-Plough, Biogenesis-Bagó and other biotech companies in Spain, Brazil, and Argentina. With a background in biochemistry and business, Patricio has acted as a change agent in several integration processes and cultivated strong leadership teams, dedicated to developing, manufacturing, and controlling biotechnological products and vaccines for human and animal health.
Patricio holds an MBA from UCEMA and a Biochemist degree from the University of Buenos Aires.
Vijay Raghavan became the Chief Financial Officer for AGC Biologics in January 2020. Vijay joined the company as Senior Vice President of Global Finance in April 2018, and has been a dedicated member and leader of the team, driving organizational growth through strategic financial planning, treasury, reporting and accounting. As CFO, Vijay continues to build value for the company, ensuring that AGC Biologics optimizes resource use to support the health and growth of our company and our customers. Vijay joined AGC Biologics after several years working in finance leadership roles at Cray and Microsoft. He leverages his 25 years of progressive experience in accounting, finance, business partnerships, strategic planning, and reporting for companies ranging from startups to conglomerates.
Outside of work, Vijay is dedicated to community service, including leadership positions at Hopelink and the Indian Association of Western Washington. Vijay earned a Masters of Commerce, Accounting, and Banking from the University of Madras in India, and an M.B.A. from the University of Hartford.
Kasper Møller was appointed to the role of Chief Technical Officer in June 2019, after serving for two years as General Manager and Site Head for our Copenhagen facility. Throughout his 14 years at AGC Biologics, Kasper has provided expertise in process characterization and validation, in previous roles such as Principal Scientist, Department Manager within Process Development, Vice President of Process Development and Vice President of Manufacturing. Earlier in his career, Kasper spent five years as an assistant professor and faculty member at the Technical University of Denmark, conducting research, and teaching fermentation technology and metabolic engineering.
Kasper earned a Ph.D. in Biochemical Engineering, with a focus on microbial physiology, from the Technical University of Denmark. He pursued his post-doc at the university’s Center for Process Biotechnology, as well as the Department of Genetics at Washington University Medical School in St. Louis. Along the way, he contributed to more than a dozen scientific international journals and publications.
Mark joined AGC Biologics in February 2018, as Senior Vice President of Integration Management and Business Excellence. He brings 25 years as a management consulting industry leader and C-level client advisor. After principal positions at Capgemini and Celerant, Mark founded his own boutique consultancy, J.W. Webb Inc., and guided many of the world's renowned companies to achieve record highs in revenue and profit, leaving behind a Fortune 500 list of stronger leaders. He began his professional journey in the military, leading a succession of U.S. Navy units to unprecedented results.
Mark holds an Executive Management Certification from Harvard Business School, a Master of Science in Organizational Development from Chapman University, and a Bachelor of Science in Education from Southern Illinois University.
Daisy Szabo, Executive Vice President of Human Resources, joined AGC Biologics in April 2017, and is responsible for strategic business alignment, process improvement for restructuring and growth, talent acquisition, change management, and operational excellence. Daisy brings more than 18 years of strategic experience, across industries including financial services, high-tech, and power generation, in environments ranging from startups to Fortune 100 companies, across Asia and the Americas. Daisy takes a cross-cultural approach to cultivating a workforce, having owned her own company in the apparel industry import distribution.
Daisy is a board member for Open Doors USA. She earned her Bachelor’s of Commerce from McGill University, and a Master of Business Administration from Azusa Pacific University. She completed the Executive Education program at University of Washington's Foster School of Business.
As Executive Vice President, Global Quality, Paul Tsang is accountable for the company’s pharmaceutical quality system across the manufacturing network. Having joined CMC Biologics in 2015 as Vice President, US Quality, he became a member of the AGC Biologics executive team in 2017 and led the successful integration of quality systems across the three companies that became AGC Biologics. Paul brings nearly 30 years of experience in the CMC development and commercialization of numerous protein and small-molecule products. His expertise includes specification development, product comparability and regulatory strategy. Prior to joining the company, he held positions of increasing responsibility at Amgen and Eli Lilly in Operations, Quality and Analytical Development roles at the site, corporate and global level.
Paul is involved in our community and industry. He is the life sciences sector representative on the Business & Philanthropy Leadership Committee for the governor’s Career Connect Washington initiative. He earned a Ph.D. in chemistry from Texas A&M University and a Bachelor of Science in applied chemistry from Harvey Mudd College.
Hiroshi Nishimura was appointed Senior Vice President, Corporate and Strategic Planning, in January 2020 after 33 years with AGC Inc. Prior to his recent appointment, Hiroshi served as Chief Financial Officer of AGC Biologics operations at the Seattle-based company headquarters for two years. Since joining Asahi Glass Company (now AGC Inc.), he has been engaged in a variety of assignments, including purchasing, sales of architectural glass, and corporate planning. In the late 90’s, Hiroshi pivoted toward sales operations in the U.S., with a focus on glass products imported from Japan. In 2016, Hiroshi joined our Life Science team as a leader of Planning and Accounting Management. With a focus on driving strategic business initiatives and fostering relationships with AGC headquarters, Hiroshi remains a vital part of the organization.
Hiroshi began his career by earning a bachelor’s degree in law from Tokyo University.
Jeffrey D. (J.D.) Mowery, Executive Vice President, United States Operations, is an industry veteran with more than 20 years of industry experience. Originally joining the team as the General Manager and Site Head for the Copenhagen, Denmark facility in 2019, J.D. led a period of strong growth with a customer centric focus and high operational standards. He is pivoting to facilitate the Boulder site rollout and ensure that workflow progress and excellence is maintained at the Seattle site, where his leadership, broad operational acumen, and results oriented methodology are invaluable. Throughout his career, J.D. has won awards for his team-driven approach while working with industry-leading companies including Juno Therapeutics (Celgene), Lonza and Genentech to support more than 25 commercial launches for biologics, cell therapies, generics and biosimilars.
J.D. earned a Bachelor of Science from George Fox University, and a Master of Business Administration at Marylhurst University, both in Oregon. He is considered a key opinion leader and respected industry contributor on the topics of aseptic processing, cell therapy and viral vector manufacturing.
Andrea C. Porchia — General Manager and Site Head, Copenhagen Facility
Andrea C. Porchia, General Manager and Site Head of the Copenhagen facility, joined AGC Biologics in August 2013. During her time with the company, she has taken on increasing responsibility across sites in progressive roles as Project Director, Senior Director Business Development, and Global Vice President of Project Management prior to the GM appointment. Andrea’s deep knowledge of the Copenhagen site is complemented by a track record of successful integration and standardization of project management practices across sites at AGC Biologics. With more than 20 years of experience in CMC development, her expertise includes process and analytical development, tech transfer, drug substance and drug product manufacturing and regulatory strategy.
Andrea pursued her education in Argentina and Denmark. She earned a PhD in Biochemistry from Mar del Plata University, Buenos Aires, Argentina, in addition to a Postdoctoral position from The Royal Veterinary and Agricultural University, Copenhagen, Denmark.
As the General Manager and Site Head of the Heidelberg facility, Dieter Kramer applies two decades of technical and leadership expertise. Dieter joined AGC Biologics in July 2018, having worked in a similar role at Corden Biochem GmbH, a full-service Contract Manufacturing Organization. Dieter brings breadth and depth to his role. Combining the disciplines of business and chemical engineering, he held various positions in R&D, manufacturing, project management and general management in the Sandoz/Novartis network in Austria and Germany. In particular, he spent five years as Managing Director of an API manufacturing site with large-scale fermentation and downstream capabilities.
Dieter pursued his education in Austria. He earned a Master of Business Administration from Management Center Innsbruck. He received his master’s degree in Technical Chemistry and Biotechnology at the Technical University of Graz. He completed his education at Höhere Technische Bundeslehranstalt in Wels with advanced study in chemical engineering.
Jun Takami — General Manager and Site Head, Chiba Facility
Jun Takami, Site Head of AGC Biologics’ facility in Chiba, joined AGC Inc. in 2017 and has since served two years as the Project Management Director at our Japan site. Jun brings over 15 years of experience in the pharmaceutical industry with roles in process development, GMP manufacturing, process engineering and PLI activities with Roche group at Chugai Pharmaceuticals.
Jun Takami holds master in biological science from Kobe University as well as a bachelor’s degree.
Luca Alberici, General Manager and Site Head at the Milan, Italy site is a value driven professional who came to AGC Biologics through the July 2020 acquisition of MolMed, a leading cell and gene therapy company. His rich educational background is complemented by more than 14 years of industry experience in roles of increasing responsibility for strategic business development and operations, licensing, project management and intellectual property for large molecule and specialty drug development and commercialization. Throughout his career, Luca has been fundamental in licensing and strategic supply agreements that drove top line results in his former position as Chief Business Officer at MolMed. In addition to practical proficiency with discovery and development for HIV and tumor therapies in his early career, Luca has extensive experience in negotiating go-to-market strategies and bringing new cell and gene therapies to market through partnerships with leading biopharmaceutical companies.
Luca earned a PhD and Masters in cellular and molecular biology from Libera Università Vita-Salute San Raffaele, in addition to a Master of Business Administration (MBA) from SDA Bocconi. He has a thorough understanding of European regulatory requirements and pricing policies, and is a published author and frequent industry speaker.